Ascletis Pharma Inc.

Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity

- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical…